Posts Tagged: alzheimers medication

• Jul 27, 2010

  No Comments

  Mercury(II) promotes the in vitro aggregation of tau fragment corresponding to the second repeat of microtubule-binding domain: Coordination and conformational transition

  The loss of metal homeostasis and the toxic effect of metal ion are important events in neurodegenerative and age-related diseases, such as Alzheimer's disease (AD). For the first time, we investigated the impacts of mercury(II) ions on the folding and aggregation of Alzheimer's tau fragment R2 (residues 275-305: VQIIN KKLDL SNVQS KCGSK DNIKH VPGGGS), corresponding...
  
  

• Jul 27, 2010

  No Comments

  Nanoimaging for protein misfolding diseases

  Misfolding and aggregation of proteins are widespread phenomena leading to the development of numerous neurodegenerative disorders such as Parkinson's, Alzheimer's, and Huntington's diseases. Each of these diseases is linked to structural misfolding and aggregation of a particular protein. The aggregated forms of the protein induce the development of a particular disease at all levels, leading...
  
  

• Jul 27, 2010

  No Comments

  FDA Approves High-Dose Donepezil for Advanced Alzheimer’s Disease

  The FDA has approved donepezil HCl 23-mg tablets for the once-daily treatment of moderate to severe Alzheimer's disease. Medscape Medical News (Source: Medscape Today...
  
  

• Jul 27, 2010

  No Comments

  More Education Delays Dementia Signs–But Not Damage

  Education has been liked to decreased risk for dementia for decades, but researchers behind a new study opened up the brains of hundreds of people who had died with the disease to try to find out why this correlation exists. [More]
  
  
  

• Jul 27, 2010

  No Comments

  Pair of Studies Link Vitamin D, Cognitive Ability in Seniors

  Two recent studies indicate that vitamin D intake can have a significant effect on the cognitive abilities of the elderly. Unfortunately, more than half of older Americans have insufficient levels of vitamin D, according to David Llewellyn, Ph.D., a researcher at the University of Exeter Peninsula Medical School, United Kingdom. Llewellyn presented data on this...
  
  

• Jul 27, 2010

  No Comments

  Eisai Inc. And Pfizer Inc Announce U.S. FDA Approval For New Higher-Dose Aricept(R) 23 Mg Tablet For The Treatment Of Moderate-To-Severe AD

  Eisai Inc. and Pfizer Inc [NYSE: PFE] announced that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer's disease (AD). Aricept 23 mg tablet offers another dosing option for patients with moderate-to-severe AD, for whom few treatments are...
  
  

• Jul 26, 2010

  No Comments

  Volunteers in Birmingham step up to launch Memory Walk.

  Volunteers put on their walking shoes last week to launch Alzheimer's Society's first flagship Memory Walk in Birmingham. (Source: Alzheimers...
  
  

• Jul 26, 2010

  No Comments

  Differences in Medication Use in the Alzheimers Disease Neuroimaging Initiative: Analysis of Baseline Characteristics

  (Source:...
  
  

• Jul 26, 2010

  No Comments

  Race affects caregiver caring, grieving

  HONOLULU, July 26 (UPI) -- A U.S. researcher says race or ethnicity may affect how best to help Alzheimer's patients' caregivers as they care or grieve for a relative. Health - Alzheimer's disease - Caregiver - United States - Alzheimer (Source: Health News -...
  
  

• Jul 26, 2010

  No Comments

  US FDA approves 23mg tablet formulation of donepezil (Aricept)

  Source: BioSpace.com Area: News According to a report by BioSpace, the US Food and Drug Administration has approved a once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer's disease (AD).   The approval of donepezil 23 mg tablet is based on data from a head-to-head study of Aricept 23...